Is tumor bed boost necessary in patients who achieved ypCR following neoadjuvant chemotherapy and breast conserving therapy? (KROG 12-05 and 16-16)
- Won Kyung Cho; Won Park; Doo Ho Choi; Yong Bae Kim; Chang-Ok Suh; Kyung Hwan Shin; Eui Kyu Chie; Jin Ho Kim; Seung Do Ahn; Su Ssan Kim; Kyubo Kim; Jin Hee Kim; Sung Ja Ahn; Sun Young Lee; Jeongshim Lee; Sang-Won Kim; Jeanny Kwon; Ki Jung Ahn; Hyun Soo Shin; Hyung Sik Lee; Nam Kwon Lee
- Dept. of Radiation Oncology (방사선종양학)
- Issue Date
- Breast, Vol.45() : 43-47, 2019
This multi-institutional study intended to investigate the effect of tumor bed boost in patients who achieved pathologic complete response (ypCR) following neoadjuvant chemotherapy (NAC) and breast-conserving therapy (BCT).
Materials and methods:
We identified 180 patients who initially had lymph node (LN) metastasis and achieved ypCR (ypT0/isN0) following NAC and BCT from the 13 institutions of the Korean Radiation Oncology Group (KROG) 16-16 and KROG 12-05. The effect of tumor bed boost on loco-regional control (LRC), disease-free survival (DFS), and overall survival (OS) rates was analyzed.
In all patients, five-year LRC, DFS and OS rates were 97.5%, 95.4%, and 99.4%, respectively. Tumor bed boost was performed in 158 (87.8%) patients. Advanced N-stage (cN2-3, p ¼ 0.036), close resection margin (p < 0.001), and sentinel lymph node biopsy (p ¼ 0.040) were unfavorable factors for DFS. Tumor bed boost was not a significant factor for LRC, DFS, and OS.
- Breast cancer; Neoadjuvant chemotherapy; Tumor bed boost; Radiotherapy
- Appears in Collections:
- 1. Journal Papers (연구논문) > 1. School of Medicine (의과대학) > Dept. of Radiation Oncology (방사선종양학)
- Keimyung Author(s)
- Full Text
- File in this Item
- RIS (EndNote)
- XLS (Excel)